Craig-Hallum lowered the firm’s price target on OmniAb (OABI) to $7 from $10 and keeps a Buy rating on the shares. The firm notes the company reported several positive developments this quarter, driven by strong business momentum and a growing network of 104 active partners. Additionally, Craig-Hallum believes that the launch of OmniUltra, following last quarter’s introduction of the xPloration Partner Access Program, should facilitate the development of new classes of biologically derived peptide therapeutics and this innovation will drive further partnerships.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OABI: